Fresenius Medical Care (FMS) expects profit growth to surge in 2025 as dialysis demand in its key US market continues to recover and it squeezes out more cost savings. Chief Executive Officer Helen Giza speaks on the company reducing its workforce by 8,200 employees and divesting 230 facilities in 2024. In the US, underlying same-market treatment growth remained positive, driven by an overall increase in patient volumes and higher reimbursement rates. The company is also preparing to roll out more advanced dialysis machines there. "We're feeling really good about the momentum and seeing that really continue" in 2025, Giza says. She speaks to Lizzy Burden, Anna Edwards and Kriti Gupta on 'Bloomberg: The Opening Trade'.

Bloomberg videos, provided by MT Newswires